Aside from not proof reading the copy the logic seems flawed in this statement:

"Given his knowledge of this industry -- and the many lessons learned from Exubera's failure -- Dance's product could be an improved, next-generation insulin that might better serve the needs of diabetes patients. Its product is still in early development, but this is (a) something investors should keep an eye on."

Just because somebody was associated with a screw up doesn't mean they learn from the mistake. That would be like naming our current president to be the Fed chairman after racking up 8 years of trillion dollar deficits.

This article seems more like FUD for MNKD and pumping Dance to me. Why would Dance be more capable of bringing an inhaled insulin to market if as is indiacted earlier in the article it is unclear whether or not inhaled insulin will be embraced by the market? Absolutely nothing is said regarding the efficacy, safety or benefits of Afrezza.

Swing